Lipoprotein(a) [ Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease. Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited.
This book offers an authoritative and comprehensive overview of Lipoprotein(a). It provides an in-depth review of all aspects of Lp(a), from pathophysiology to metabolism. Chapters offer the reader a contemporary view of the important roles of Lp(a) as a risk factor for cardiovascular disease. In addition, this volume discusses the clinical implications of elevated Lp(a) and current and future therapies.
Lipoprotein(a) is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.
60 years of Lp(a) research-From Ouchterlonys double diffusion to a
significant risk factor for CHD.- Lp(a) structure and composition.- Genetics
of Lipoprotein(a).- Lp(a) metabolism.- Contemporary aspects of Lp(a)
metabolism and therapies based on tracer kinetic methods.- Role of Proprotein
Convertase Subtilisin Kexin type 9 in Lipoprotein(a) Metabolism.- The Role of
Cell Surface Receptors in Lp(a) Metabolism.- Physiological Roles And
Functions Of Lipoprotein(a).- The role of Lp(a) in Atherosclerosis: An
overview.- Role of macrophages in Lp(a) pathophysiology.- Thrombosis,
Inflammation and Lipoprotein(a): Clinical Implications .- The role of the
kidney in Lp(a) physiology and pathophysiology.- Lp(a) as a cardiovascular
risk factor.- Lp(a) and aortic valve stenosis, stroke, and other non-coronary
cardiovascular diseases.- Lp(a) in cardiovascular disease: Evidence from
Large Epidemiological Studies.- Lipoprotein(A) And Immunity.- When to measure
Lp(a) .- Measurement of Lipoprotein (a) in the Clinical Laboratory.-
Standardization of analytical methods for the measurement of Lipoprotein(a):
bridging past and future initiatives.- Establishing an SI-traceable
Reference Measurement System for Lp(a), based on Quantitative Protein Mass
Spectrometry and Molar Units.- Compounds that impact Lp(a) concentrations.-
Antisense oligonucleotide therapy to treat elevated lipoprotein(a).-
Lipoprotein apheresis for reduction of Lipoprotein(a).- Elevated Lp(a) - Why
Should I Test For It, If I Cannot Treat It? A Patients Perspective .-
Burning unanswered questions Therapy.
Karam Kostner, MD, Ph.D., FRACP, FCSANZ
Associate Professor of Medicine
University of Queensland and Mater Hospital
Brisbane, Australia
Gerhard M. Kostner, Ph.D.
Emeritus Professor of Biochemistry and Molecular Biology
Medical University of Graz, Austria
Graz, Austria
Peter P. Toth, M.D. , PhD, FAHA, FESC, FACC
Adjunct Professor of Medicine
Division of Cardiology
Johns Hopkins University School of Medicine
Baltimore, Maryland USA
